← All trials
NCT06020716
Phase 4Interventional
Studies of FDA-approved drugs to delineate additional information including the drug's risks, benefits, and optimal use.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Aug 16, 2023
- Primary completion
- Apr 30, 2028
- Completion date
- Apr 30, 2028
- First posted
- Sep 1, 2023
- Last posted
- Sep 1, 2023
- Enrollment
- 350
- Arms / groups
- 4 / —
- Source
- AACT · ctgov ingestion
Sponsors
- University of StavangerLead sponsor
- Helse Møre og Romsdal HFCollaborator
- Norwegian University of Science and TechnologyCollaborator
- University of OsloCollaborator
- University of BergenCollaborator
- Northern Norway Regional Health AuthorityCollaborator
- University of StavangerStudy chair
- Oslo Metropolitan UniversityCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.